government
Biden-Harris administration keen on GLP1s
The outgoing Biden-Harris admin puts out a proposal on widening access to GLP1s, which we hope the incoming Trump admin will also adopt.
category:news
country:uk
The UK's bet on GLP1
A look at the UK's growing evaluation and use of GLP1 receptor agonists -- Ozempic, Mounjaroy, Wegovy, Zepbound and more.
category:news
Viking Therapeutic's new GLP1 impresses at ObesityWeek 2024
At ObesityWeek 2024, Viking Therapeutic showed study results on their new drug VK2735 -- 8% body weight loss at 28 days, in the highest dose.
category:news
FDA reconsidering Tirzepatide shortage list removal
After legal action by a group of compounders, the FDA is reviewing their removal of Tirzepatide (Mounjaro, Zepbound) from the shortage list.
category:news
Compounders sue FDA over Tirzepatide shortage changes
Compounders sue FDA for removing Eli Lilly's weight loss drug from the shortage list. Does the case have legs?
category:news
Why the Tirzepatide shortage ending might be bad news.
Bad news that sounds like good news: FDA ends shortage Eli Lilly's GLP-1 (Tirzepatide). We'll tell you why that's bad news.
category:news
GLP1s and Sleep Apnea
GLP1s (in particular Tirzepatide, created by Eli Lilly) have positive effects on Sleep Apnea
category:news
Insurers continue to embrace Virtual Healthcare for GLP1s
Omada is moving from virtual health into the wider field of wellness programs, enhancing their offering. We dig into what's changed.
categeory:watercooler
Novo's CEO will testify, but change is unlikely
Novo's CEO goes to congress to testify, but not much is likely to change in the drug's pricing. We dive into some historical context.
drug:am-133
Amgen's GLP1: MariTide (formerly AMG-133)
Amgen is working on a new GLP1, entering the race -- AM-133. We dig into the trials and research and see if it's got any promise.
company:eli-lilly
Eli Lilly's other new GLP1 - Orforglipron
Eli Lilly is developing new GLP1 drugs, and Orforglipron is one of them. It's not easy to pronounce, but it is easy to take, and easy to produce.
category:news
23andMe gets into GLP1
23andMe leaves drug discovery, but embraces providing GLP1 Receptor Agonists -- emphasizing a shift to active preventative care.